Friends! In this video, I'm going to talk about ASML stock, ADOBE stock & OTIS stock
3 extracted signals · 3 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 19 Aug 2025, 22:23 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The video discusses three stock picks the presenter likes, even though the overall S&P 500 market is trading at high valuations. The first stock analyzed is ASML, currently priced at $742.16; the presenter believes its growth hasn't fully reflected in the market, considering it the toll bridge to innovation. He notes ASML's significant market share in semiconductor lithography, coupled with double-digit revenue growth in its installed base management segment. The risk he assigns is the dependence on China. Secondly, the presenter considers Adobe at a PE of 16 attractive, and suggests it has solid fundamentals, despite bad market sentiment; as it is a software business with a high percentage of recurring revenues and a dividend. Finally, OTIS at $87.43 trades below its average earnings and has strong service businesses with steady cashflows; the downside is China as well.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
3 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.